Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeting Iatrogenic Cushing's Syndrome with 11β-HSD1 Inhibition
2016-003060-40Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of AZD4017 in Cushing's syndrome and insulin resistance (IR), sponsored by University of Oxford. Primary endpoint: Change in glucose disposal. Started Dec 2016; status: completed.
02
Drugs
AZD4017
03
Conditions
Cushing's syndromeinsulin resistance (IR)
Beyond the preview
Go deeper on 2016-003060-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003060-40.